Disruption of White Matter Integrity by Chronic Cerebral Hypoperfusion in Alzheimer's Disease Mouse Model

Journal of Alzheimer's Disease

Volumn 52, Issue 4, 2016, Pages 1311-1319

  Zhai, Yun ^a   Yamashita, Toru ^a   Nakano, Yumiko ^a   Sun, Zhuoran ^a   Morihara, Ryuta ^a   Fukui, Yusuke ^a   Ohta, Yasuyuki ^a   Hishikawa, Nozomi ^a   Abe, Koji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; APP23 mice; galantamine; hypoperfusion; white matter mater lesion

Indexed keywords

ANKYRIN; ANKYRIN G; GALANTAMINE; MYELIN ASSOCIATED GLYCOPROTEIN; NFASC186 PROTEIN; SODIUM CHANNEL NAV1.6; UNCLASSIFIED DRUG; ANK3 PROTEIN, MOUSE; CELL ADHESION MOLECULE; NERVE GROWTH FACTOR; NFASC PROTEIN, MOUSE; NOOTROPIC AGENT;

AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXON; BRAIN PERFUSION; BRAIN REGION; CAROTID ARTERY OBSTRUCTION; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS CALLOSUM; DRUG EFFICACY; GLIA; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANVIER NODE; WHITE MATTER; WHITE MATTER LESION; ANIMAL; BRAIN ISCHEMIA; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; ANKYRINS; BRAIN ISCHEMIA; CELL ADHESION MOLECULES; CORPUS CALLOSUM; DISEASE MODELS, ANIMAL; GALANTAMINE; MALE; MICE; MICE, INBRED C57BL; MYELIN-ASSOCIATED GLYCOPROTEIN; NERVE GROWTH FACTORS; NOOTROPIC AGENTS; WHITE MATTER;

EID: 84974633287     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160120     Document Type: Article

References (35)

1. Fields RD (2008) White matter in learning, cognition and psychiatric disorders. Trends Neurosci 31, 361-370.
2. Sousa AD, Bhat MA (2007) Cytoskeletal transition at the paranodes: The Achilles' heel of myelinated axons. Neuron Glia Biol 3, 169-178.
3. Barber R, Scheltens P, Gholkar A, Ballard C, McKeith I, Ince P, Perry R, O'Brien J (1999) White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatry 67, 66-72.
4. Hirono N, Kitagaki H, Kazui H, Hashimoto M, Mori E (2000) Impact of white matter changes on clinical manifestation of Alzheimer's disease: A quantitative study. Stroke 31, 2182-2188.
5. Stewart R (2001) Cerebral white matter lesions and subjective cognitive dysfunction: The Rotterdam scan study. Neurology 57, 2149.
6. Hishikawa N, Yamashita T, Deguchi K, Wada J, Shikata K, Makino H, Abe K (2015) Cognitive and affective functions in diabetic patients associated with diabetes-related factors, white matter abnormality and aging. Eur J Neurol 22, 313-321.
7. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, Kalaria RN, Forster G, Esteves F, Wharton SB, Shaw PJ, O'Brien JT, Ince PG (2006) White matter lesions in an unselected cohort of the elderly: Molecular pathology suggests origin from chronic hypoperfusion injury. Stroke 37, 1391-1398.
8. Bores GM, Huger FP, Petko W, Mutlib AE, Camacho F, Rush DK, Selk DE, Wolf V, Kosley RW, Jr., Davis L, Vargas HM (1996) Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 277, 728-738.
9. Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, Maelicke A (1996) Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 49, 1-6.
10. Ezoulin MJ, Ombetta JE, Dutertre-Catella H, Warnet JM, Massicot F (2008) Antioxidative properties of galantamine on neuronal damage induced by hydrogen peroxide in SKN-SH cells. Neurotoxicology 29, 270-277.
11. Satapathy SK, Ochani M, Dancho M, Hudson LK, Rosas-Ballina M, Valdes-Ferrer SI, Olofsson PS, Harris YT, Roth J, Chavan S, Tracey KJ, Pavlov VA (2011) Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice. Mol Med 17, 599-606.
12. Takata K, Kitamura Y, Saeki M, Terada M, Kagitani S, Kitamura R, Fujikawa Y, Maelicke A, ToMIMOto H, Taniguchi T, Shimohama S (2010) Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem 285, 40180-40191.
13. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer diseaselike pathology. Proc Natl Acad Sci U S A 94, 13287-13292.
14. Winkler DT, Bondolfi L, Herzig MC, Jann L, Calhoun ME, Wiederhold KH, Tolnay M, Staufenbiel M, JuckerM(2001) Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci 21, 1619-1627.
15. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R (2010) Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 107, 7036-7041.
16. Roher AE, Debbins JP, Malek-Ahmadi M, Chen K, Pipe JG, Maze S, Belden C, Maarouf CL, Thiyyagura P, Mo H, Hunter JM, Kokjohn TA, Walker DG, Kruchowsky JC, Belohlavek M, Sabbagh MN, Beach TG (2012) Cerebral blood flow in Alzheimer's disease. Vasc Health Risk Manag 8, 599-611.
17. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Russell RW, Symon L (1975) Cerebral blood flow in dementia. Arch Neurol 32, 632-637.
18. Lopez PH (2014) Role of myelin-associated glycoprotein (siglec-4a) in the nervous system. Adv Neurobiol 9, 245-262.
19. Yin X, Crawford TO, Griffin JW, Tu P, Lee VM, Li C, Roder J, Trapp BD (1998) Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci 18, 1953-1962.
20. Aboul-Enein F, Rauschka H, Kornek B, Stadelmann C, Stefferl A, Bruck W, Lucchinetti C, Schmidbauer M, Jellinger K, Lassmann H (2003) Preferential loss of myelinassociated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol 62, 25-33.
21. Zhan X, Cox C, Ander BP, Liu D, Stamova B, Jin LW, Jickling GC, Sharp FR (2015) Inflammation combined with ischemia produces myelin injury and plaque-like aggregates of myelin, amyloid-beta and abetaPP in adult rat brain. J Alzheimers Dis 46, 507-523.
22. Susuki K, Rasband MN (2008) Molecular mechanisms of node of Ranvier formation. Curr Opin Cell Biol 20, 616-623.
23. Waxman SG, Craner MJ, Black JA (2004) Na+channel expression along axons in multiple sclerosis and its models. Trends Pharmacol Sci 25, 584-591.
24. Sherman DL, Tait S, Melrose S, Johnson R, Zonta B, Court FA, Macklin WB, Meek S, Smith AJ, Cottrell DF, Brophy PJ (2005) Neurofascins are required to establish axonal domains for saltatory conduction. Neuron 48, 737-742.
25. Moll C, Mourre C, Lazdunski M, Ulrich J (1991) Increase of sodium channels in demyelinated lesions of multiple sclerosis. Brain Res 556, 311-316.
26. Tuvia S, Garver TD, Bennett V (1997) The phosphorylation state of the FIGQY tyrosine of neurofascin determines ankyrin-binding activity and patterns of cell segregation. Proc Natl Acad Sci U S A 94, 12957-12962.
27. Einheber S, Bhat MA, Salzer JL (2006) Disrupted axo-glial junctions result in accumulation of abnormal mitochondria at nodes of ranvier. Neuron Glia Biol 2, 165-174.
28. Cao L, He C (2013) Polarization of macrophages and microglia in inflammatory demyelination. Neurosci Bull 29, 189-198.
29. Prineas JW, Graham JS (1981) Multiple sclerosis: Capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol 10, 149-158.
30. Merson TD, Binder MD, Kilpatrick TJ (2010) Role of cytokines as mediators and regulators of microglial activity in inflammatory demyelination of the CNS. Neuromolecular Med 12, 99-132.
31. Howell OW, Palser A, Polito A, Melrose S, Zonta B, Scheiermann C, Vora AJ, Brophy PJ, Reynolds R (2006) Disruption of neurofascin localization reveals early changes preceding demyelination and remyelination in multiple sclerosis. Brain 129, 3173-3185.
32. Waxman SG (2006) Axonal conduction and injury in multiple sclerosis: The role of sodium channels. Nat Rev Neurosci 7, 932-941.
33. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ (2003) Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421, 384-388.
34. Bencherif M (2009) Neuronal nicotinic receptors as novel targets for inflammation and neuroprotection: Mechanistic considerations and clinical relevance. Acta Pharmacol Sin 30, 702-714.
35. SuYA, Huang RH, Wang XD, Li JT, Si TM(2014) Impaired working memory by repeated neonatal MK-801 treatment is ameliorated by galantamine in adult rats. Eur J Pharmacol 725, 32-39.